The majority of patients who take baby or coated aspirin to prevent strokes are not getting the blood-thinning results they may need to help avoid these health threats, according to preliminary research presented today at the American Stroke Association’s 28th International Stroke Conference. The American Stroke Association is a division of the American Heart Association. “While research has established that aspirin reduces the risk of stroke in patients with cerebrovascular disease, the optimal dose and formulation still remains somewhat unclear,” according to Mark Alberts, M.D., the study’s lead author and director of the Stroke Program at Northwestern Memorial Hospital. “This study is significant in that it points researchers in the right direction ? showing how we can maximize the effectiveness of aspirin.”